Proficio Capital Partners LLC increased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,859 shares of the company’s stock after purchasing an additional 429 shares during the period. Proficio Capital Partners LLC’s holdings in Johnson & Johnson were worth $2,625,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in JNJ. Nordwand Advisors LLC acquired a new position in Johnson & Johnson in the fourth quarter worth about $785,273,000. Vanguard Group Inc. grew its stake in Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after buying an additional 2,815,655 shares during the last quarter. GQG Partners LLC grew its stake in Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after buying an additional 2,547,378 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Johnson & Johnson by 37.2% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after buying an additional 1,805,632 shares during the last quarter. Finally, First Trust Advisors LP grew its stake in Johnson & Johnson by 62.6% during the first quarter. First Trust Advisors LP now owns 2,785,312 shares of the company’s stock worth $493,640,000 after buying an additional 1,072,104 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.
Analyst Ratings Changes
Several research firms have recently commented on JNJ. SVB Leerink decreased their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. StockNews.com began coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They set a “strong-buy” rating on the stock. Guggenheim began coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target on the stock. UBS Group assumed coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target on the stock. Finally, Piper Sandler lowered their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $173.07.
Johnson & Johnson Trading Down 2.8 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The company had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. Johnson & Johnson’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.67 EPS. Research analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current year.
Insider Transactions at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.20% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
See Also
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Gamida Cell Stock Jumps Over 100% on FDA Approval
- Insiders Buy EasyJet, Regularly And Repeatedly
- Bank of America Beats Earnings, Renews Investor Upside Potential
- The Analysts See A Bright Future For Sunrun
- J.B. Hunt: Economic Contraction And A Buying Opportunity
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
